In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Highlights Mavenclad Advances In Tough Quarter

Executive Summary

Merck KGaA's brace of new products started to garner sales in the third quarter, but the big pharma maintained its 2017 guidance at the lower end of the forecast range in the face of increasing competition to its established pharmaceutical products and to its liquid crystal materials, and currency headwinds.

You may also be interested in...



Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems

Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.

Executive Interview: Building Merck KGaA's Specialty Business In EMEA

It’s an interesting challenge, commercializing in Europe the first novel pharmaceuticals to be developed and launched by Merck KGaA in a decade. The new head of its EMEA region explains his approach to the task.

Don’t Miss The Train: Pharma's Future Holds Deeper Digital Deals, Outcome-Based Pacts

Asked by Scrip to name two big changes coming pharma's way, Merck KGAA Healthcare CEO Belén Garijo identified artificial intelligence and outcome-based pacts as 'ways of the future'.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel